Announcements Trials
Browse Landscape

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 3092Neoplasms 2436Carcinoma, Non-Small-Cell Lung 1863Prostatic Neoplasms 1617Colorectal Neoplasms 1422Lung Neoplasms 1292Multiple Myeloma 927Neoplasm Metastasis 919Leukemia, Myeloid, Acute 874Pancreatic Neoplasms 847Ovarian Neoplasms 799Melanoma 783Carcinoma, Hepatocellular 736Stomach Neoplasms 639Brain Neoplasms 635Recurrence 633Squamous Cell Carcinoma of Head and Neck 630Head and Neck Neoplasms 609Glioblastoma 566Lymphoma 539Uterine Cervical Neoplasms 537Triple Negative Breast Neoplasms 504Precursor Cell Lymphoblastic Leukemia-Lymphoma 499Carcinoma, Renal Cell 497Hematologic Neoplasms 462Urinary Bladder Neoplasms 459Endometrial Neoplasms 459Colonic Neoplasms 441Lymphoma, Non-Hodgkin 435Sarcoma 434

Interventions

darolutamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Non-metastatic Castration-resistant Prostate Cancer × 1 year × Clear all
NCT07538843 2026-05-15

DARE

Bayer

Not yet recruiting
800 enrolled
Genitourinary

Non-metastatic Castration-resistant Prostate Cancer

NCT06334120 2026-05-13

An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

Bayer

Recruiting
600 enrolled
Genitourinary

Non-metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡